H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The gross proceeds from this offering were approximately $3.2 million.
The ADSs described above were offered pursuant to a "shelf" registration statement (File No. 333-237542) filed with the
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function.
Investor Relations
Stern Investor Relations
IR@StealthBT.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering-301180012.html
SOURCE
Amelia Stetler, 617-762-2562
media@stealthbt.com